{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Gieselmann L"],"funding":["European Research Council","NIAID NIH HHS","Gates Foundation"],"pubmed_abstract":["Administration of HIV-1 neutralizing antibodies can suppress viremia and prevent infection <i>in vivo</i>. However, clinical use is challenged by broad envelope sequence diversity and rapid emergence of viral escape<sup>1-9</sup>. Here, we performed single B cell profiling of 32 top HIV-1 elite neutralizers to identify broadly neutralizing antibodies (bNAbs) with highest potency and breadth for clinical application. From 831 expressed monoclonal antibodies, we identified 04_A06, a new V<sub>H</sub>1-2-encoded CD4 binding site bNAb with remarkable breadth and potency against extended multiclade pseudovirus panels (GeoMean IC<sub>50</sub> = 0.059 μg/ml, breadth = 98.5%, 332 virus strains). Moreover, 04_A06 was not susceptible to classic viral CD4bs escape variants and maintained full viral s"],"journal":["bioRxiv : the preprint server for biology"],"pagination":["2025.08.27.672638"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12407976"],"repository":["biostudies-literature"],"pubmed_title":["Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy."],"pmcid":["PMC12407976"],"funding_grant_id":["U01 AI169385","R01 AI140891","724208","P01 AI100148","INV-036842","INV-002143","U54 AI170856"],"pubmed_authors":["West AP","Giovannoni F","Rohde M","Hoelscher M","Zhang L","Havenar-Daughton C","Ercanoglu MS","Kroidl A","Bjorkman PJ","Corti D","Lehmann C","Benigni F","Adhikari A","Ambada GE","Gilbert PB","DeLaitsch AT","Stumpf R","Knufer J","Gristick HB","Reichwein ML","Mkhize NN","Stefanutti E","Kaldine H","Worczinski J","Doria-Rose NA","Moore PL","Mora T","Ntinginya NE","Geldmacher C","Duerr R","Schommers P","Seaman MS","Gieselmann L","Nanfack AJ","Radford C","Gruell H","Wolf T","William W","Ahmadov E","Maganga L","Walczak AM","Momot A","Mazzolini A","Klein F","Bloom JD","Kreer C","Huang Y","Deshpande S","Bhebhe S"],"additional_accession":[]},"is_claimable":false,"name":"Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy.","description":"Administration of HIV-1 neutralizing antibodies can suppress viremia and prevent infection <i>in vivo</i>. However, clinical use is challenged by broad envelope sequence diversity and rapid emergence of viral escape<sup>1-9</sup>. Here, we performed single B cell profiling of 32 top HIV-1 elite neutralizers to identify broadly neutralizing antibodies (bNAbs) with highest potency and breadth for clinical application. From 831 expressed monoclonal antibodies, we identified 04_A06, a new V<sub>H</sub>1-2-encoded CD4 binding site bNAb with remarkable breadth and potency against extended multiclade pseudovirus panels (GeoMean IC<sub>50</sub> = 0.059 μg/ml, breadth = 98.5%, 332 virus strains). Moreover, 04_A06 was not susceptible to classic viral CD4bs escape variants and maintained full viral s","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-04-08T19:48:33.213Z","creation":"2026-04-08T14:33:21.099Z"},"accession":"S-EPMC12407976","cross_references":{"pubmed":["40909752"],"doi":["10.1101/2025.08.27.672638"]}}